Study to Assess Adverse Events and How ABBV-932 Oral Capsules Moves Through the Body of Healthy Adult Participants

Study Identifier
M23-889
CT.gov Identifier
NCT05738850
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Study Details

Medical Condition
  • Anxiety
  • Healthy Volunteer
    • Study Drug
  • ABBV-932
  • Placebo
    • Phase
    Phase 1
    Sex
    Female & Male
    Age
    18 - 65 Years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Parts 1 and 2: Healthy individuals with body-mass index (BMI) \>= 18.0 to \<= 32.0 kg/m2, rounded to the tenths decimal. * Part 3: Healthy Japanese, Han Chinese individuals with BMI \>= 18.0 to \<= 30.0 kg/m2, rounded to the tenths decimal. * Condition of general good health based upon the results of a medical history, physical examination, vital signs, laboratory profile, neurological examination, and a 12-lead ECG.
    Exclusion Criteria:
    \- History of any clinically significant illness/infection/major febrile illness, hospitalization, or any surgical procedure within 30 days prior to the first dose of study drug.

    Protocol Summary

    The main objective of this study is to assess pharmacokinetics, safety, and tolerability of ABBV-932 in healthy adult participants.

    Study Locations

    Location
    Status
    Location
    Anaheim Clinical Trials LLC /ID# 254178
    Anaheim, California, United States, 92801-2658
    Status
    Not applicable
    Location
    Acpru /Id# 249639
    Grayslake, Illinois, United States, 60030
    Status
    Not applicable